HepaRegeniX, a Tübingen, Germany-based preclinical stage company developing a novel therapy for the treatment of acute and chronic liver diseases, closed an over €11M Series B financing round.
Backers included Boehringer Ingelheim Venture Fund GmbH (BIVF), Novo Holdings A/S, the High-Tech Gründerfonds, Coparion and Ascenion.
The company intends to use the funds to advance the MKK4 inhibitor for treatment of acute and chronic liver diseases to the clinics later in 2020.
Led by Dr. Michael Lutz, CEO, HepaRegeniX has discovered and developed several preclinical drug candidates for the treatment of acute and chronic liver diseases based on a novel proprietary molecular target Mitogen-Activated Protein (MAP) Kinase 4. MKK4 is a key regulator of liver regeneration and suppression of MKK4 unlocks the regenerative capacity of hepatocytes even in severely diseased livers.
This new therapeutic concept for the treatment of liver diseases was discovered by Prof. Lars Zender and his research group at the University Hospital Tubingen, Germany.